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Abstract
We report the ﬁnal analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic
leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were
randomized 1:1 to ofatumumab (300 mg ﬁrst week, followed by 1000 mg every 8 weeks for up to 2 years) or
observation. Median follow-up duration was 40.9 months. Median progression-free survival was 34.2 and 16.9 months
for ofatumumab and observation arms, respectively, (hazard ratio, 0.55 [95% conﬁdence interval, 0.43–0.70]; P < 0.0001).
Median time to next treatment for ofatumumab and observation arms, respectively, was 37.4 and 27.6 months (0.72
[0.57–0.91]; P= 0.0044). Overall survival was similar in both arms; median was not reached (0.99 [0.72–1.37]). Grade ≥ 3
adverse events occurred in 62% and 51% of patients in ofatumumab and observation arms, respectively, the most
common being neutropenia (23% and 10%), pneumonia (13% and 12%) and febrile neutropenia (6% and 4%). Up to
60 days after the last treatment, four deaths were reported in the ofatumumab arm versus six in the observation arm,
none considered related to ofatumumab. Ofatumumab maintenance signiﬁcantly prolonged progression-free survival
in patients with relapsed CLL and was well tolerated.
Introduction
As of 2018, chronic lymphocytic leukemia (CLL)
remains an incurable disease. Therefore, prolonged
progression-free survival (PFS) and overall survival (OS)
with good quality of life remain the most important
treatment goals. Improvement in PFS can result from
more effective induction treatment, and further pro-
longation may be obtained by maintenance therapy. In
2015, we published results of a planned interim analysis of
PROLONG, an open-label, randomized, phase III study
that evaluated ofatumumab, a human type I CD20
monoclonal antibody (mAb), as maintenance treatment in
patients with CLL who are in at least partial remission
(PR) after induction treatment for relapse. Major
conclusions were that ofatumumab maintenance com-
pared with observation resulted in signiﬁcant improve-
ment in PFS and was well tolerated1. Here we report the
ﬁnal analysis results for key primary and secondary end-
points of the study. Final analysis was triggered by
protocol-deﬁned 280 investigator-assessed PFS events.
Materials and methods
Study design and patients
PROLONG (ClinicalTrials.gov identiﬁer: NCT01039
376) was an open-label, randomized, phase III study
conducted at 130 centers in 24 countries in patients with
CLL in complete remission (CR) or PR (according to the
International Workshop on CLL [IWCLL] updated
National Cancer Institute-Working Group [NCI-WG]
guidelines2) after second- or third-line treatment. The
inclusion and exclusion criteria have been previously
described1. The study was conducted according to the
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Declaration of Helsinki and Good Clinical Practice
guidelines and approved by the institutional review boards
of all participating institutions. Written informed consent
has been obtained.
Randomization and treatment
Randomization (1:1) to ofatumumab or observation was
stratiﬁed by response at entry (CR or PR), number of
previous induction treatments (2 or 3) and type of the
most recent treatment (chemoimmunotherapy, alkylating
monotherapy or other treatment). Crossover was not
allowed between study arms.
Within 1 week of treatment assignment, patients in the
ofatumumab arm started with intravenous 300 mg treat-
ment, followed 1 week later by 1000mg every 8 weeks for
up to 2 years. Dose reductions were not allowed; however,
interruption or delay of administration because of adverse
events (AEs) was permitted. Patients were treated until
disease progression, withdrawal from study treatment due
to unacceptable AEs, consent withdrawal or other rea-
sons. Patients who prematurely discontinued study
treatment were included in the analysis regardless of
treatment duration.
Assessment of efﬁcacy and safety
Study parameters assessed at study entry and during
follow-up have been previously described1. AEs were
measured using the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0.
The primary endpoint was investigator-assessed PFS,
deﬁned as the time from randomization to the earliest
date of disease progression or death due to any cause. For
patients who did not progress or die, PFS was censored at
the time of last adequate assessment. In addition, PFS was
censored for patients who received new anticancer
treatment before disease progression and for those with 2
or more missing assessments. Secondary endpoints
included OS, time to next treatment (TTNT), PFS after
next-line therapy (deﬁned as the time from randomization
until progression or death following next-line therapy)
and safety. Responses were deﬁned and assessed accord-
ing to IWCLL updated NCI-WG guidelines2.
Fig. 1 PROLONG study CONSORT diagram. ITT intent-to-treat.
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Statistical analysis
Final analysis was conducted when a minimum of 280
events of disease progression or death occurred, which
was needed to detect the targeted 40% improvement in
PFS (hazard ratio [HR], 0.71) difference with 80% power
and 5% two-sided α level. Efﬁcacy analyses were con-
ducted on the intent-to-treat (ITT) population regardless
of the actual treatment received. Safety analysis was based
on the actual treatment received. PFS, OS, TTNT and
PFS after next-line therapy were analyzed using a strati-
ﬁed log-rank test adjusted for stratiﬁcation factors.
Kaplan–Meier curves were generated to determine dif-
ferences between survival distributions of the treatment
arms. All P values are two-sided. Statistical analyses were
performed using SAS software (version 9.3; SAS Institute,
Cary, NC, USA).
Results
Patients and treatment
Between 31 May 2010 and 01 October 2014, 609
patients were screened. A total of 480 patients, including
six additional patients enrolled since interim analysis,
were randomized to ofatumumab maintenance (n= 240)
or observation (n= 240) (Fig. 1). All 480 patients were
included in ITT analyses. One patient from the ofatu-
mumab arm did not receive the allocated intervention
(withdrew consent) and was therefore included in the
observation arm for safety analysis. At the time of ﬁnal
analysis (cutoff date, 20 February 2017), 146 (30.5%)
patients had died, and disease progression had occurred in
267 (56%) patients (Fig. 1).
Baseline demographics and clinical characteristics were
well balanced between the study arms (Table 1). In total,
385 (80%) patients were in PR, 94 (20%) were in CR and 1
(<1%) had missing data. Overall, 337 (70%) patients had
received 2 prior treatments. The most recent treatment
was chemoimmunotherapy in 386 (80%) patients, pri-
marily ﬂudarabine, cyclophosphamide and rituximab
(53%) and bendamustine and rituximab (24%), while only
23 (5%) patients had received alkylating monotherapy
(Table 1); of note, 403 (84%) patients had previously
received a rituximab-containing treatment regimen.
Overall, 186 (78%) patients received 100% and 42 (18%)
received 80% to <100% of the assigned ofatumumab dose.
Only 11 (5%) patients received <80% of the expected total
ofatumumab dose. Primary reasons for ofatumumab dis-
continuation included AEs (12%), the most frequent being
neutropenia (2%), refusal/withdrawal by patient (3%), phy-
sician decision (5%) and protocol deviation (<1%; Fig. 1).
Efﬁcacy
At the time of ﬁnal analysis, the median follow-up
duration was 40.9 months. Compared with observation,
ofatumumab maintenance resulted in signiﬁcant and
Table 1 Demographics and baseline disease
characteristicsa.
Ofatumumab
(n= 240)
Observation
(n= 240)
Age, yearsb
Median (min–max) 64.0 (33–86) 64.5 (39–87)
<70, n (%) 167 (70) 166 (69)
≥70, n (%) 73 (30) 74 (31)
≥75, n (%) 42 (18) 35 (15)
Sex, n (%)
Female 79 (33) 80 (33)
Male 161 (67) 160 (67)
Time since diagnosis, median
(range) in year
6.0 (1–22) 5.0 (1–22)
Response to last CLL treatment, n (%)
CR 47 (20) 47 (20)
PR 193 (80) 192 (80)
Missing 0 1 (<1)
Baseline MRD, n (%)
Negative 31 (13) 42 (18)
Positive 139 (58) 107 (45)
Missing 70 (29) 91 (38)
No. of prior treatments, n (%)
2 169 (70) 168 (70)
3 67 (28) 63 (26)
Other 4 (2) 9 (4)
Type of last prior treatment, n (%)
Chemoimmunotherapy 193 (80) 193 (80)
BR 46 (24) 48 (25)
FCR 100 (52) 105 (54)
FR 4 (2) 5 (3)
Other 30 (16) 24 (12)
RCVP 13 (7) 11 (6)
Alkylating monotherapy 14 (6) 9 (4)
Other 33 (14) 38 (16)
Baseline cytogenetics, n (%)c
11q deletion 15 (6) 13 (5)
17p deletion 7 (3) 4 (2)
6q deletion or 12q trisomy
or 13q deletion
47 (20) 16 (7)
No aberration 151 (63) 174 (73)
Missing 20 (8) 33 (14)
van Oers et al. Blood Cancer Journal            (2019) 9:98 Page 3 of 9
Blood Cancer Journal
clinically relevant improvement in the primary endpoint.
Investigator-assessed PFS was 34.2 months (95% con-
ﬁdence interval [CI], 29.7–38.0) for the ofatumumab arm
versus 16.9 months (95% CI, 13.0–20.4) for the observa-
tion arm (HR, 0.55 [95% CI, 0.43–0.70]; P < 0.0001; Fig.
2a). Assessment of PFS by the independent review com-
mittee yielded similar results: 33.6 months (95% CI,
28.0–37.2) for the ofatumumab arm versus 15.0 months
(95% CI, 11.4–19.0) for the observation arm (HR, 0.57
[95% CI, 0.46–0.72]; P < 0.0001). When events detected by
computed tomography scan were also included, the
investigator-assessed PFS was shorter (ofatumumab
maintenance 27.5 months [95% CI, 23.0 to 30.2] versus
observation 13.1 months [95% CI, 11.6–16.9]; HR, 0.64
[95% CI, 0.52–0.78]; P < 0.0001). The improved PFS did
not translate into a difference in OS, and median OS was
not reached in both arms (HR, 0.99 [95% CI, 0.72–1.37];
Fig. 2b). As shown in the forest plots (Fig. 3), the PFS
beneﬁt was evident in most subgroups, including baseline
demographic characteristics (age and gender), response at
study entry, type of prior therapy, baseline minimal resi-
dual disease (MRD) (Supplementary Fig. 1) and immu-
noglobulin variable heavy-chain gene (IGVH) mutation
status. A clear exception was patients with 17p deletion at
relapse on study who did not beneﬁt from ofatumumab
maintenance treatment. Although patients with 17p
deletion at baseline (i.e., at study entry) seem to beneﬁt
from ofatumumab maintenance, this group is very small,
precluding robust conclusions. Unfortunately, results of
cytogenetic testing performed at the time of original CLL
diagnosis were not available.
Subsequent treatment was administered to 133 (55%)
patients in the ofatumumab arm and 155 (65%) patients in
the observation arm. Ofatumumab maintenance improved
TTNT compared with observation (37.4 months [95% CI,
30.6–42.6] versus 27.6 months [95% CI, 23.5–32.6],
respectively; HR, 0.72 [95% CI, 0.57–0.91]; P= 0.004; Fig.
4a). PFS after next-line therapy was deﬁned as the time
from randomization to the second objective disease pro-
gression or death from any cause, whichever occurred ﬁrst.
Patients who did not progress or die after next-line therapy
were censored at their last date of contact. PFS after next-
line treatment was not different between the two arms
(median not reached; HR, 0.88 [95% CI, 0.49–1.61]; Fig.
4b). Steroids and some antineoplastic agents (i.e., ritux-
imab, cyclophosphamide, chlorambucil) were used slightly
more frequently for next treatment in the observation arm.
Interestingly, follow-up therapy for the ofatumumab arm
versus the observation arm comprised ofatumumab for 1
(<1%) versus 15 (9%) re-treated patients, idelalisib for 5
(3%) versus 11 (7%) patients, ibrutinib for 54 (35%) versus
48 (29%) patients, acalabrutinib for 2 (1.3%) versus 0 (0%)
patients and venetoclax for 4 (3%) versus 3 (2%) patients,
respectively. Thus, about 40% of patients received novel
agents as next-line treatment.
Toxicity
Both the total number of AEs and number of grade ≥ 3
AEs were higher in the ofatumumab arm than in the
observation arm (Table 2). An increased incidence of
grade ≥ 3 neutropenia was observed in the ofatumumab
arm compared with the observation arm (23% [56/239]
versus 10% [24/241]). Prolonged and severe neutropenia,
deﬁned as grade 3 or 4 neutropenia occurring during the
treatment period and not resolved at least 42 days after
the last dosing date, occurred in 11/239 (5%) patients in
the ofatumumab maintenance arm and 4/241 (2%)
patients in the observation arm. The increased incidence
of grade ≥ 3 neutropenia likely contributed to the
observed increase in grade ≥ 3 infections in patients in the
ofatumumab (31% [73/239]) versus observation (25% [60/
241]) arms. The use of growth factor support was repor-
ted 58 times among the 239 patients in the ofatumumab
maintenance safety population versus 24 times in the 241
patients in the observation arm. At study entry, in both
study arms, median immunoglobulin (Ig) A and IgM
levels were decreased, whereas IgG levels were just above
the lower limit (Supplementary Fig. 2). During the treat-
ment phase, IgM, IgG, and IgA levels did not change
signiﬁcantly in the ofatumumab arm. In contrast, in the
observation arm, serum IgM levels gradually increased to
just above the lower limit of normal, whereas IgG and IgA
levels did not change. During follow-up, IgM levels
showed a slight increase in the ofatumumab arm.
Unfortunately, beyond 30 months of follow-up, these
small values preclude robust conclusions. Peripheral
blood B cells began recovering 3 months after the end of
ofatumumab maintenance (data not shown).
Only 4% (9/239) of patients experienced grade ≥ 3
infusion-related AEs, which were deﬁned as events
Table 1 continued
Ofatumumab
(n= 240)
Observation
(n= 240)
IGVH mutational status, n (%)
Mutated 54 (23) 74 (31)
Unmutated 139 (58) 116 (48)
Not available 3 (1) 1 (<1)
Missing 44 (18) 49 (20)
BR bendamustine and rituximab, CLL chronic lymphocytic leukemia, CR
complete remission, FCR ﬂudarabine, cyclophosphamide, and rituximab, FR
ﬂudarabine and rituximab, IGVH immunoglobulin variable heavy-chain gene, ITT
intent-to-treat, MRD minimal residual disease, PR partial remission, RCVP
rituximab, cyclophosphamide, vincristine, and prednisone
aITT population
bAge was calculated from birth date to screening date in years
c12% cutoff
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occurring during infusion or within 24 h after completion
of infusion, which the investigator attributed to the
treatment medication. These events included, but were
not limited to, chills, dyspnea, ﬂushing, hypotension,
nausea, pain, pruritus, pyrexia, rash and urticaria. AEs
that led to treatment discontinuation occurred in 12%
(28/239) of patients in the ofatumumab arm.
During the period from the ﬁrst dose to 60 days after the
last dose, four deaths were reported in the ofatumumab arm
(one event each of pneumonia, cerebral haemorrhage,
sepsis and small bowel obstruction) and six in the obser-
vation arm (two subdural haematoma, one fever and gastric
pain, one intestinal infarction, one cardiac arrest, and one
disease progression). None of these deaths were attributed
to the study drug. At the time of ﬁnal analysis, a total of 146
(30%) patients had died: 76 (32%) in the ofatumumab arm
and 70 (29%) in the observation arm. Disease under study
was the most frequent cause of death, with 46 (19%) deaths
in the ofatumumab arm and 35 (15%) in the observation
arm. Fatal serious AEs occurred in 26 (11%) patients in the
ofatumumab arm and 33 (14%) patients in the observation
arm. Of note, extremely few occurrences of Richter trans-
formation (none in the ofatumumab arm versus 2 in the
observation arm) were observed.
Discussion
Final analysis of the PROLONG study conﬁrmed the
interim analysis results1 and showed that ofatumumab
maintenance improved both PFS and TTNT in patients
with relapsed CLL and was well tolerated. The PFS beneﬁt
was independent of baseline demographic characteristics,
remission status at study entry, prior treatments and IGVH
mutation status. Ofatumumab maintenance was accom-
panied by an increased risk of grade 3/4 neutropenia and
grade 3/4 infections. Importantly, ofatumumab main-
tenance did not increase the risk of Richter transformation
nor did it impair the response to next-line treatment.
Although the values are relatively small and our study
was not powered to compare these subgroups, the beneﬁt
of ofatumumab seems more pronounced in the MRD-
negative subgroup (Supplementary Fig. 1). This is an
important ﬁnding because it shows that patients with
Fig. 2 ITT analysis of a PFS, as assessed by investigator, and b OS. ITT: intent-to-treat; OS: overall survival; PFS: progression-free survival.
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good response to induction therapy may beneﬁt from
additional maintenance therapy. Greil et al. did not ﬁnd
any signiﬁcant improvement in PFS with rituximab
maintenance in patients with CLL who were MRD
negative after ﬁrst- or second-line treatment3. Results of
long-term follow-up in their lesser pre-treated patient
group would certainly be of interest.
Analyses of the cytogenetic subgroups (Fig. 3) should be
interpreted with caution because of the very low number
of patients with positive testing; this is most likely because
patients were in PR or CR at study entry, resulting in
levels of cytogenetic abnormalities below the detection
threshold, notably in MRD-negative patients. This implies
that the group without cytogenetic abnormalities harbors
patients with chromosomal aberrations. Unfortunately,
data on cytogenetics before study entry were not available.
In addition, the low number of patients with 17p deletion
might be partially attributable to the fact that these
patients probably would not have been considered for
participation in our study because they were candidates
for other treatment modalities, such as allogeneic stem
cell transplantation or treatment with kinase inhibitors.
The conclusion that the PFS beneﬁt with ofatumumab
maintenance is independent of IGVH mutation status was
based on an analysis of a robust number of patients,
despite 26% of patients missing data in both study arms.
Fig. 3 Forest plot of subgroup analysis of PFS. β2M β2-microglobulin; CI conﬁdence interval; CR complete remission; HR hazard ratio; IGVH
immunoglobulin variable heavy-chain gene; MRD minimal residual disease; PFS progression-free survival; PR partial remission.
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In our study, the interval between progression and next
treatment appeared to be longer in the observation arm
than in the maintenance arm (Figs. 2a and 4a). More rapid
disease progression due to a possible difference in the
biology of relapse was not supported by the observed
similar PFS after next-line treatment in both study arms
(Fig. 4b). Alternatively, lymphocytosis (not necessitating
rapid treatment) might be a more frequent mode of pro-
gression in the observation arm than in the maintenance
arm as long as there is circulating antibody. However, this is
not supported by peripheral lymphocyte counts at relapse,
which, although slightly lower in the maintenance arm,
were not different between the two study arms (Supple-
mentary Table 1). Because CLL progression as such is not
an indication to start next treatment, TTNT is susceptible
to subjectivity and, therefore, a less robust endpoint com-
pared with PFS. Whether the threshold for initiation of
treatment for progression during or after maintenance
versus observation was different is speculative. PFS after
next-line treatment (consisting of kinase inhibitors in ~40%
of patients) in this cohort with 2 or 3 prior treatments is
quite remarkable and reﬂects the progress that has been
made in treatment of patients with relapsed CLL.
With longer follow-up, toxicity data were very similar to
those found in the interim analysis1. Ofatumumab
maintenance was associated with an increase in grade ≥ 3
neutropenia and infections, which was comparable to
ﬁndings from studies on maintenance therapy with the
chimeric anti-CD20 mAb rituximab in both follicular
lymphoma4 and CLL3. No unexpected toxicity was
observed. We have previously shown that no clinically
relevant differences in health-related quality of life
between the two study arms at any time point during
treatment were observed1.
At the time of interim analysis in 2014, results of only
one randomized phase III trial of maintenance treatment
in CLL had been published1. In a study of 201 newly
diagnosed or previously treated patients with CLL,
Fig. 4 Time to next-line treatment and PFS after next-line treatment. a TTNT and b PFS after next-line treatment, deﬁned as the time from
randomization to the second disease progression or death from any cause, in patients receiving next-line treatment for relapse in the study. CLL
chronic lymphocytic leukemia; PFS progression-free survival; TTNT time to next treatment.
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rituximab maintenance for 2 years was found to improve
PFS and OS but only in high-risk (11q and 17p) patients5.
Since then, four other randomized phase III studies have
been reported. First, ﬁnal analysis of a multicenter trial on
rituximab maintenance for 2 years in 263 patients with
CLL (77% after ﬁrst-line and 23% after second-line treat-
ments) showed a median PFS of 47 months in the ritux-
imab arm versus 35.5 months in the observation arm (HR,
0.50 [95% CI, 0.33–0.75]; P= 0.0007). Median OS was not
reached in either arm. Grade 3 to 4 neutropenia occurred
in 21% of patients in the rituximab arm versus 11% in the
observation arm, with grade ≥ 3 infections in 20% versus
10% of patients, respectively3. Second, in a randomized,
double-blind, placebo-controlled, phase III trial conducted
in 314 previously treated patients with CLL, lenalidomide
maintenance given until disease progression improved
median PFS from 9.2 months in the observation arm to
33.9 months in the lenalidomide arm (HR, 0.40 [95% CI,
0.29 to 0.55]; P < 0.0001) but did not improve OS. The
most common grade 3 or 4 AEs were neutropenia (lena-
lidomide arm [60%] versus placebo arm [23%]) and
thrombocytopenia (17% versus 6%)6. Third, a randomized,
double-blind, phase III study was performed in 89 high-
risk patients with CLL, deﬁned as those having post
induction intermediate or high MRD levels combined with
an unmutated IGVH gene status or TP53 alterations.
Lenalidomide maintenance after ﬁrst-line therapy admi-
nistered until disease progression improved the median
PFS (13.3 months in the placebo arm versus not reached in
the lenalidomide arm; HR, 0.168 [95% CI, 0.074–0.379];
P < 0.0001) but not OS. Grade ≥ 3 neutropenia occurred in
60% of patients in the lenalidomide arm versus 23% in the
control arm7. In a French study, 409 treatment-naïve and
ﬁt patients with CLL aged ≥ 65 years in CR or PR after
induction with four cycles of ﬂudarabine, cyclopho-
sphamide and rituximab were randomized to rituximab
maintenance or observation. Median PFS in the rituximab
arm (59.3 months) was greater compared with the obser-
vation arm (49.0 months) (HR, 0.55; P= 0.0002). Neu-
tropenia and grade 3 to 4 infections were more common
with rituximab maintenance versus observation (53%
versus 36 and 19% versus 10%, respectively)8.
Table 2 Any AEs in ≥2% (grade ≥ 3) of patients by haematologic toxicity and infections.
All Grade Grade ≥ 3
Preferred term Ofatumumab (n= 239) Observation (n= 241) Ofatumumab (n= 239) Observation (n= 241)
Any event, n (%) 209 (87) 168 (70) 105 (44) 74 (31)
Haematologic toxicity, n (%)
Neutropenia 64 (27) 27 (11) 56 (23) 24 (10)
Febrile neutropenia 17 (7) 11 (5) 14 (6%) 9 (4%)
Thrombocytopenia 14 (6) 15 (6) 5 (2) 8 (3)
Anaemia 9 (4) 15 (6) 5 (2) 7 (3)
Neutrophil count decreased 8 (3) 3 (1) 5 (2) 2 (<1)
Infections, n (%)
Pneumonia 42 (18) 41 (17) 32 (13) 28 (12)
Pyrexia 51 (21) 31 (13) 12 (5) 6 (2)
Sepsis 7 (3) 5 (2) 7 (3) 5 (2)
Septic shock 5 (2) 1 (<1) 5 (2) 1 (<1)
Lung infection 4 (2) 4 (2) 4 (2) 3 (1)
Upper respiratory tract infection 54 (23) 28 (12) 4 (2) 1 (<1)
Herpes zoster 17 (7) 12 (5) 3 (1) 4 (2)
Urinary tract infection 13 (5) 12 (5) 2 (<1) 5 (2)
Cellulitis 5 (2) 5 (2) 2 (<1) 4 (2)
Respiratory tract infection 18 (8) 18 (7) 2 (<1) 4 (2)
Infusion-related reaction, n (%) 42 (18) 0 3 (1) 0
AEs as reported by the investigator
Infusion-related reactions were deﬁned as events occurring during infusion or within 24 h after completion of infusion and included chills, dyspnea, ﬂushing,
hypotension, nausea, pain, pruritus, pyrexia, rash, and urticaria
AE adverse event
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Taken together, these six randomized phase III studies,
four of which included an anti-CD20 mAb, clearly
demonstrate the clinical beneﬁt of maintenance treatment
in CLL. In all these studies maintenance treatment was
applied after induction treatment with chemoimmu-
notherapy. One might argue that our data are less relevant
in the present era of promising data on the use of novel
agents in CLL, notably Bruton’s tyrosine kinase inhibi-
tors9,10, phosphatidylinositol-3-kinase inhibitors11 and
BCL-2 antagonists12,13. Indeed, depending on the out-
come of ongoing trials in previously untreated patients
comparing “chemofree” induction regimens consisting of
(a combination of) novel agents with induction treatment
with chemoimmunotherapy, it is expected that upfront
use of chemoimmunotherapy in high-risk CLL patients
will decrease. However, at present the possible role of
chemoimmunotherapy in patients relapsing after prior
use of (multiple) novel agents is unclear. Thus for relapsed
patients (the population investigated in our trial) our
ﬁndings might still be relevant. Importantly, thus far the
novel agents are all recommended to be continued until
relapse, leading to a very prolonged maintenance therapy,
despite the limited availability of robust data on long-term
safety, including risk of infections, emergence of mutated
resistant clones14,15 and Richter transformation16. Results
of ongoing studies on efﬁcacy of kinase inhibitors and
BCL-2 antagonists when used for a more restricted period
would be relevant for assessment of optimal use of these
drugs. In this setting, head-to-head comparisons of efﬁ-
cacy and safety of (prolonged) maintenance therapy with
novel drugs versus anti-CD20 mAbs such as ofatumumab
are relevant to determine optimal maintenance strategies
for patients with CLL. In such studies, quality of life and
cost-effectiveness should be important secondary
endpoints.
Acknowledgements
We thank the patients and investigators in the PROLONG study for their
participation. We thank Saurabh Agarwal for editorial assistance. The study was
funded by GlaxoSmithKline (GSK) and later by Novartis. GSK provided the study
drug and worked with the HOVON and Nordic CLL group in the development
of the study design. GSK and Novartis worked with the HOVON and Nordic CLL
group for collection and interpretation of data.
Author details
1Academisch Medisch Centrum and HOVON, Amsterdam, The Netherlands.
2University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic.
3Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 4Universitair Ziekenhuis
Gent, Gent, Belgium. 5Department of Hematology and Cancer Prevention,
Silesian Medical University, Katowice, Poland. 6Albert Schweitzer Ziekenhuis
Dordrecht and HOVON, Dordrecht, The Netherlands. 7Novartis Oncology, East
Hanover, NJ, USA. 8Novartis Pharma AG, Basel, Switzerland. 9Rigshospitalet-
Koebenhavn, Copenhagen, Denmark
Conﬂict of interest
M.V.O. serves as a consulting or advisory role at Roche, ISA Therapeutics and
Immunicum and provides expert testimony for Roche. L.S. and M.-D.L. have
received honoraria, consulting fees and travel, accommodation and expenses
from Roche, Janssen, AbbVie and Gilead. Both also served on speakers’ bureau
for Gilead. J.D. and P.H. are both employed by and hold stock or other
ownership of Novartis. T.S. and H.B. are employees of Novartis. M.P., F.O., S.G.,
and C.G. have no relationships to disclose.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41408-019-0260-2).
Received: 10 July 2019 Revised: 18 October 2019 Accepted: 7 November
2019
References
1. van Oers, M. H. et al. Ofatumumab maintenance versus observation in
relapsed chronic lymphocytic leukemia (PROLONG): an open-label, multi-
center, randomized phase 3 study. Lancet Oncol. 16, 1370–1379 (2015).
2. Hallek, M. et al. International Workshop on Chronic Lymphocytic Leukemia.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a
report from the International Workshop on Chronic Lymphocytic Leukemia
updating the National Cancer Institute-Working Group 1996 guidelines. Blood
111, 5446–5456 (2008).
3. Greil, R. et al. Rituximab maintenance versus observation alone in patients with
chronic lymphocytic leukemia who respond to ﬁrst-line or second-line ritux-
imab-containing chemoimmunotherapy: ﬁnal results of the AGMT CLL-8a
Mabtenance randomized trial. Lancet Haematol. 3, e317–e329 (2016).
4. Vidal, L. et al. Rituximab maintenance for the treatment of patients with
follicular lymphoma: an updated systematic review and meta-analysis of
randomized trials. J. Natl. Cancer Inst. 103, 1799–1806 (2011).
5. Huang, B. T., Zeng, Q. C., Zhao, W. H., Li, B. S. & Chen, R. L. How to determine
post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic
lymphocytic leukemia, maintenance rituximab or observation. Med. Oncol. 31,
104 (2014).
6. Chanan-Khan, A. A. et al. Lenalidomide maintenance therapy in previously
treated chronic lymphocytic leukemia (CONTINUUM): a randomized, double-
blind, placebo-controlled, phase 3 trial. Lancet Haematol. 4, e534–e543 (2017).
7. Fink, A. M. et al. Lenalidomide maintenance after ﬁrst-line therapy for high-risk
chronic lymphocytic leukemia (CLLM1): ﬁnal results from a randomized,
double-blind, phase 3 study. Lancet Haematol. 4, e475–e486 (2017).
8. Dartigeas, C. et al. Rituximab maintenance versus observation following
abbreviated induction with chemoimmunotherapy in elderly patients with
previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-
label, randomized phase 3 study. Lancet Haematol. 5, e82–e94 (2018).
9. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic
leukemia. N. Engl. J. Med. 369, 32–42 (2013).
10. Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lym-
phocytic leukemia. N. Engl. J. Med. 373, 2425–2437 (2015).
11. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic
leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
12. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic
lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016).
13. Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic
leukemia with 17p deletion: a multicenter, open-label, phase 2 study. Lancet
Oncol. 17, 768–778 (2016).
14. Komarova, N. L., Burger, J. A. & Wodarz, D. Evolution of ibrutinib resistance in
chronic lymphocytic leukemia (CLL). Proc. Natl Acad. Sci. USA 111,
13906–13911 (2014).
15. Woyach, J. A. et al. Resistance mechanisms for the Bruton’s tyrosine kinase
inhibitor ibrutinib. N. Engl. J. Med. 370, 2286–2294 (2014).
16. Chang, B. Y. et al. Use of tumor genomic proﬁling to reveal mechanisms of
resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
J. Clin. Oncol. 31(Suppl. 15), 7014 (2013).
van Oers et al. Blood Cancer Journal            (2019) 9:98 Page 9 of 9
Blood Cancer Journal
